Results 111 to 120 of about 38,272 (314)

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes?:A prospective, double-blind, randomised, placebo-controlled study [PDF]

, 2017
Background: Patients with diabetes have a two to fourfold increased risk for development of and death from cardiovascular disease [CVD]. The current oral hypoglycaemic agents result in limited reduction in this cardiovascular risk.
A Dawson, A Ilercil, A Merovci, A Oberman, A Patel, Alexander J.M. Brown, Allan Struthers, B Zinman, C Majewski, Chim Lang, D Vasilakou, DW Brown, DZ Cherney, E Angelantonio Di, E Ferrannini, G Howard, G Mancia, G Simone de, IM Stratton, J Bolinder, J Bolinder, JA Dorresteijn, JB Buse, JH Shubrook, JP Despres, K Wachtell, LH Lindholm, M Mizamtsidi, M Ridderstrale, MA Nauck, MJ Koren, MK Rutter, N Chaturvedi, P Verdecchia, P Verdecchia, P Verdecchia, PM Okin, PM Okin, PM Okin, R Chilton, R Fraser, RB Devereux, RB Devereux, Rory McCrimmon, RR Holman, RS Cooper, RV Oliva, S Kalra, S Rekhraj, SM Artham, SM Haffner, UK Prospective Diabetes Study [UKPDS] Group, W Duckworth, WL Baker, WT Cefalu, Y Liao, Z Abassi   +56 more
core   +2 more sources

Retracted: Dapagliflozin Inhibits Ventricular Remodeling in Heart Failure Rats by Activating Autophagy through AMPK/mTOR Pathway [PDF]

, 2023
Computational and Mathematical Methods in Medicine
openalex   +1 more source

Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial

Cardiovascular Diabetology
Background Although several previous studies tested SGLT2 inhibitors in the setting of an acute, non-cardiovascular illness, detailed information on their efficacy and safety among participants with and without type 2 diabetes (T2D) from double-blind ...
Mohammad Abdel Jawad, Remo H. M. Furtado, Russell Esterline, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Anna Maria Langkilde, Philip Ambery, Shachi Patel, Kensey Gosch, Sheryl L. Windsor, Ronaldo V. P. Soares, Diogo D. F. Moia, Matthew Aboudara, Ali Javaheri, J. F. Kerr Saraiva, Lilia Nigro Maia, Otavio Berwanger, Andrew J. Sauer, Mikhail N. Kosiborod   +22 more
doaj   +1 more source

Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease

Veterinary and Animal Science
Myxomatous mitral valve disease (MMVD) is the most common valvular heart disease in geriatric small-to medium-sized dogs. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT-2i), has shown promise in managing heart failure in human patients ...
Nakkawee Saengklub, Anusak Kijtawornrat, Robert L. Hamlin   +2 more
doaj   +1 more source

Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs:The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors) [PDF]

, 2017
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus ...
Arya, Niki, Birkeland, Kåre I., Bodegård, Johan, Cavender, Matthew A., Fenici, Peter, Fu, Alex Z., Hammar, Niklas, Holl, Reinhard W., Jørgensen, Marit Eika, Khunti, Kamlesh, Kosiborod, Mikhail, Norhammar, Anna, Thuresson, Marcus, Wilding, John P.   +13 more
core   +2 more sources

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms [PDF]

, 2018
YesRecent clinical trials of the hypoglycaemic sodium-glucose co-transporter-2 (SGLT2) inhibitors, which inhibit renal glucose reabsorption, have reported beneficial cardiovascular outcomes. Whether SGLT2 inhibitors directly affect cardiovascular tissues,
A Tenenbaum, A Woods, A Woods, AJ Scheen, B Xiao, B Zinman, C Davies, C Rutherford, C Wang, D Devineni, D Garcia, E Bess, E Ferrannini, E Ferrannini, F Naznin, HM Salim, HR Heathcote, IP Salt, IP Salt, J Bain, JG Boyle, JH Han, JM Cacicedo, JM Corton, K Pinter, K Takeuchi, KS Khabar, LA Villani, M Abdul-Ghani, M Joubert, M Oelze, MA Ewart, ML Chen, N Sattar, P Cohen, PM Ridker, S Kasichayanula, S Schreml, S Steven, S Tumova, SA Hawley, SJ Mancini, T Brand, V Makó, Y Han, Y Liang, Y Nakatsu, Y Ye, Y Zhang   +48 more
core   +4 more sources

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design [PDF]

, 2016
Background Heart failure (HF) and diabetes (DM) are a lethal combination. The current armamentarium of anti-diabetic agents has been shown to be less efficacious and sometimes even harmful in diabetic patients with concomitant cardiovascular disease ...
A Deswal, AK Wong, Allan D. Struthers, AM Kriska, AM Murcia, Amir Fathi, B Zinman, BM Scirica, C Andersson, C Majewski, Chim C. Lang, CL Aquilante, CM O’Connor, DG Kramer, DH Elder, DT Eurich, DVEM Cherney, DZ Cherney, DZI Cherney, Ewan R. Pearson, F Grothues, FMHK Younis, I Tikkanen, I Tzoulaki, Ify Mordi, J Bolinder, J. Graeme Houston, Jagdeep S. S. Singh, JB Green, JG Regensteiner, JH Shubrook, JM Evans, JN Cohn, JZ Kasa-Vubu, Keeran Vickneson, L Thomas, M Jessup, M Seibæk, MA Konstam, MA Nauck, Mohapradeep Mohan, MR MacDonald, RB Devereux, RB Devereux, RJ McCrimmon, RM Cubbon, RS Taylor, RV Oliva, S Han, S Kalra, S Mudaliar, S Rekhraj, SE Inzucchi, SL Brandenburg, SL Kristensen, SS Rathore, T Forst, VM Conraads, W Doehner, WA Hsueh, WB White, WG Members   +61 more
core   +4 more sources

Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial

Diabetes & Metabolism Journal
Background This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin. Methods In this multicenter,
Ji Hye Heo, K. Han, Jun Hwa Hong, Hyun-Ae Seo, Eun-Gyoung Hong, J. Yu, Hye Seung Jung, B. Cha   +7 more
semanticscholar   +1 more source